Jörg F. Rippmann

Boehringer Ingelheim (Germany) — Germany

Medicine · Health Sciences

15h-index823citations29works6.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Liver Disease Diagnosis and Treatment(11), Liver physiology and pathology(10), Endoplasmic Reticulum Stress and Disease(6), Peptidase Inhibition and Analysis(4), RNA Interference and Gene Delivery(3)

Publications29 total

An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer
Science Translational Medicine·2025· 3 citedOpen Access
Screening the human druggable genome identifies ABHD17B as an anti-fibrotic target in hepatic stellate cells
Nature Communications·2025· 2 citedOpen Access
Diverse potential of secretome from natural killer cells and monocyte-derived macrophages in activating stellate cells
Frontiers in Immunology·2024· 13 citedOpen Access
2284P Pre-clinical assessment of the therapeutic potential of a CD80-Fc-armed oncolytic virus (VSV-GP-CD80Fc)
Annals of Oncology·2023
Screening the human druggable genome identifies ABHD17B as an anti-fibrotic target in hepatic stellate cells
2023· 1 citedOpen Access
Nanchangmycin regulates FYN, PTK2, and MAPK1/3 to control the fibrotic activity of human hepatic stellate cells
eLife·2022· 15 citedOpen Access
Author response: Nanchangmycin regulates FYN, PTK2, and MAPK1/3 to control the fibrotic activity of human hepatic stellate cells
2022Open Access
Nanchangmycin regulates FYN, FAK and ERK to control the fibrotic activity of hepatic stellate cells
2021· 1 citedOpen Access
Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD
Scientific Reports·2021· 82 citedOpen Access
Modulation of vascular contraction via soluble guanylate cyclase signaling in a novel ex vivo method using rat precision‐cut liver slices
Pharmacology Research & Perspectives·2021· 7 citedOpen Access
Epigenetic Modification 6‐Methyladenosine Can Impact the Potency and Specificity of siRNA
ChemBioChem·2020· 11 cited
Investigating fibrosis and inflammation in an ex vivo NASH murine model
American Journal of Physiology-Gastrointestinal and Liver Physiology·2020· 21 citedOpen Access
Transcriptomic characterization of culture-associated changes in murine and human precision-cut tissue slices
Archives of Toxicology·2019· 37 citedOpen Access
PI3K inhibition reduces murine and human liver fibrogenesis in precision-cut liver slices
Biochemical Pharmacology·2019· 25 citedOpen Access
Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis
Digestive Diseases and Sciences·2018· 22 citedOpen Access
Head‐to‐head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury
British Journal of Pharmacology·2017· 27 citedOpen Access
RNAi Screen for NRF2 Inducers Identifies Targets That Rescue Primary Lung Epithelial Cells from Cigarette Smoke Induced Radical Stress
PLoS ONE·2016· 5 citedOpen Access
Off-Target Analysis of Control siRNA Molecules Reveals Important Differences in the Cytokine Profile and Inflammation Response of Human Fibroblasts
Oligonucleotides·2009· 39 cited
Comparison of the anti-allergic activity of Syk inhibitors with optimized Syk siRNAs in FcεRI-activated RBL-2H3 basophilic cells
Cellular Immunology·2009· 21 cited
Acetyl‐CoA carboxylases 1 and 2 show distinct expression patterns in rats and humans and alterations in obesity and diabetes
Diabetes/Metabolism Research and Reviews·2009· 36 cited
page 1 of 2Next →

Frequent Co-authors

Lorena Pantano(6), Julia F. Doerner(6), Shannan J. Ho Sui(6), Jennifer Y. Chen(5), Cheng Sun(5), Robert P. Sparks(5), Sean P. Moran(5), Rory Kirchner(5), David M. Wrobel(5), Alan C. Mullen(5), Wolfgang J. Rettig(4), Andreas Schnapp(4), Eric J. Simon(4), Dieter Moosmayer(4), Anouk Oldenburger(4), Wenyang Li(4), Carine M. Boustany‐Kari(3), Klaus Pfizenmaier(3), Emilia Bigaeva(3), Emilia Gore(3)